Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
Description:
This is an 8-week observational follow-up study of patients who participated in the ST-001
CALISTA study. In this ST-003 (OF-CALISTA) study, the occurrence of delayed adverse events,
standard of care treatments for calciphylaxis (medications [including Sodium Thiosulfate
Injection and pain medication], wound debridement, amputation, hyperbaric oxygen therapy, and
surgical parathyroidectomy), and calciphylaxis-related complications (new or worsening skin
lesions, ulceration, infection, sepsis and hospitalizations) will be recorded during an
8-week observation period following patient participation in the ST-001 CALISTA study (A
Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter,
Randomized, Double-blind, Placebo-controlled Clinical Trial).
Condition:
Calciphylaxis
Treatment:
Start Date:
October 20, 2017
Sponsor:
Hope Pharmaceuticals
For More Information:
https://clinicaltrials.gov/show/NCT03319914